Hepatitis A vaccine in Indonesia: safeguarding the nation's children and adolescents from overlooked risks

Read full text Summarise with VIRAT
Authors: Muhammad Gilang Dwi Putra, Rodman Tarigan Girsang, Aulia Khatib, Ayunda Sartika
Cited by: 0
References: 38

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Hepatitis A virus (HAV) is a leading cause of acute viral hepatitis worldwide, particularly in developing countries with poor sanitation, socio-demographic conditions including sexual transmitted diseases. Unlike HAV infection in children, which is generally asymptomatic, infections in adolescents and adults tend to present more severe symptoms. Indonesia is a country with intermediate HAV endemicity, with incidence rates increasing since 2007. Currently, hepatitis A vaccination is not included in the national routine immunisation program, despite the Indonesian Pediatric Society (IDAI) recommending vaccination for children starting at 12 months of age. Two types of HAV vaccines are used. Both show high efficacy in preventing HAV infection, with nearly 100% seroconversion after the second dose. Combined HAV and HBV vaccines also provide long-term protection against both viruses, maintaining high seropositivity rates up to 10 years post-vaccination. However, risks of antibody decline and local and systemic side effects remain, though these are generally well-tolerated.

Fields of Study & Subjects

Hepatitis Viruses Studies and Epidemiology Hepatitis B Virus Studies Viral gastroenteritis research and epidemiology

Publication details

Journal / source
Vaccine X
Volume
30
Pages
100810–100810
Publication date
22 March 2026
Language
EN